Catalog No.S1123 Synonyms: CB-7598
Molecular Weight(MW): 349.51
Abiraterone is a potent CYP17 inhibitor with IC50 of 2 nM in a cell-free assay.
Cited by 7 Publications
Purity & Quality Control
Choose Selective P450 (e.g. CYP17) Inhibitors
Click to view more
2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.
|Description||Abiraterone is a potent CYP17 inhibitor with IC50 of 2 nM in a cell-free assay.|
|Features||Approved for the treatment of docetaxel-treated castration-resistant prostate cancer.|
Abiraterone binds and inhibits wild-type and mutant androgen receptor (AR). Abiraterone inhibits in vitro proliferation and androgen receptor-regulated gene expression of androgen receptor-positive prostate cancer cells, which could be explained by androgen receptor antagonism in addition to inhibition of steroidogenesis. In fact, activation of mutant androgen receptor by eplerenone is inhibited by greater concentrations of Abiraterone. Abiraterone displaces ligand from both WT-AR and T877A with EC50 of 13.4 μM and 7.9 μM, respectively. Abiraterone inhibits lyase activity with an IC50 of 5.8 nM in rat testis microsomes. Abiraterone acetate significantly inhibits T secretion (−48%) and in turn increased LH concentration (192%).
|In vivo||Abiraterone inhibits CYP17 with an IC50 of 72 nM, in human testicular microsomes.  Abiraterone fails to significantly reduce the size of any of the organs.  Abiraterone reduces the testosterone levels strongly, almost reaching the level of the orchiectomy control. The testosterone levels are reduced by Abiraterone for more than 95% compared to the control group. |
C17,20-lyase activity assay:Microsomes are diluted to a final protein concentration of 50 μg/mL in the reaction mixture which contained 0.25 M sucrose, 20 mM Tris–HCl (pH 7.4), 10 mM G6P and 1.2 IU/mL G6PDH. After equilibration at 37 °C for 10 minutes, the reaction is initiated by addition of βNADP to obtain a final concentration of 0.6 mM. Prior to the distribution of 600 μL of the reaction mixture in each tube, Abiraterone is evaporated to dryness under a stream of nitrogen and then are incubated at 37 °C for 10 minutes. After incubation with Abiraterone, 500 μL of the reaction mixture is transferred to tubes containing 1 μM of the enzyme substrate, 17OHP. After a further 10 minutes incubation, tubes are placed on ice and the reaction is stopped by addition of 0.1 ml NaOH 1N. Tubes are deep-frozen and stored at −20 °C until assayed for Δ4A levels. A Δ4A RIA is developed and automated on a microplate format using a specific antibody against Δ4A. The separation of free and bound antigen is achieved with a dextran-coated charcoal suspension. After centrifugation, aliquots of the clear supernatant are counted in duplicates in a 1450 MicrobetaPlus liquid scintillation counter. The Δ4A concentrations of unknown samples are determined from the standard curve. The detection limit is 0.5 ng/mL and the within and between assay coefficients of variation are 10.7 and 17.6%, respectively at an assay value of 13 ng/mL. The rate of enzymatic reaction is expressed as pmol of Δ4A formed per 10 minutes and per mg of protein. The value of maximum activity without inhibitor (control) is set at 100%. The IC50 values are calculated using non-linear analysis from the plot of enzyme activity (%) against log of inhibitor concentration.
-  Attard G, et al. J Clin Oncol. 2008, 26(28), 4563-4571.
-  Richards J, et al. Cancer Res. 2012, 72(9), 2176-2182.
-  Duc I, et al. J Steroid Biochem Mol Biol. 2003, 84(5), 537-542.
|In vitro||DMF||4 mg/mL (11.44 mM) warming|
|Ethanol||0.2 mg/mL (0.57 mM)|
|DMSO||0.1 mg/mL (0.28 mM)|
* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT01553188||Active, not recruiting||Prostatic Neoplams|Prostate Cancer|Neoplasm, Prostate|Neoplasm,Prostatic||National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)||February 7, 2012||Phase 2|
|NCT02403505||Not yet recruiting||Stage, Prostate Cancer|Surgery||Dr. Han Xu, President/CEO / PD / PI / Monitor / IRB Chair|PPD|Medicine Invention Design, Inc||August 2020||Phase 3|
|NCT02949284||Not yet recruiting||Stage II Prostate Adenocarcinoma|Stage III Prostate Adenocarcinoma||Rutgers, The State University of New Jersey|National Cancer Institute (NCI)||June 2017||Phase 2|
|NCT02987543||Recruiting||Metastatic Castration-resistant Prostate Cancer||AstraZeneca||February 2017||Phase 3|
|NCT02789878||Not yet recruiting||Prostate Cancer||Instituto do Cancer do Estado de São Paulo|Janssen, LP||February 2017||Phase 2|
|NCT02867020||Not yet recruiting||Prostate Cancer||Latin American Cooperative Oncology Group|Janssen Pharmaceuticals||January 2017||Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.